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Abstract:Pig-to-humanxenotransplantationofisletcellsorofvascularizedorganswouldofferawelcometreat-
mentalternativefortheever-increasingnumberofpatientswithend-stageorganfailurewhoarewaitingforasuit-
ableallograph.Themainhurdlearepreexistingantibodies,mostofwhicharespecificfor‘Linear-B’,carbohydrate
epitopes terminatedby theunbranchedGal-a(1,3)Galdisaccharide.Theseantibodiesare responsible for the
‘hyper-acuterejection’ofthexenograftbycomplementmediatedhemorrhage.Fordepletionofsuchantibodies
wehavedevelopedanartificialinjectableantigen,aglycopolymer(GAS914)withachargeneutralpoly-lysine
backbone(degreeofpolymerizationn=1000)and25%ofitssidechainscoupledtoLinear-B-trisaccharide.With
anaveragemolecularweightof400to500kD,presenting250trisaccharideepitopespermolecule,thismultiva-
lentarraybindsanti-aGalantibodieswithatleastthreeordersofmagnitudehigheravidityonaper-saccharide
basisthanthemonomericepitope.In vivoexperimentswithnon-humanprimatesdocumentedthatratherlow
doses–1to5mg/kgofGAS914injectedi.v.–efficientlyreducetheloadofanti-Linear-Bantibodiesquicklyby
atleast80%.ThistreatmentcanberepeatedwithoutanysensitizationtoGAS914.Interestingly,althoughthe
antibodylevelsstartraising12hafterinjection,theydonotreachpretreatmentlevels.Thepolymerisdegraded
andexcretedwithinhours,withaminutefractionremaininginlymphoidtissueofanti-aGalproducinganimals
only,probablybindingtoandinhibitingantibody-producingB-cells.Theresultsofpig-to-non-humanprimate
xenotransplantationsestablishedGAS914asarelevanttherapeuticoptionforpig-to-humantransplantationsas
well.ThesynthesisofGAS914wassuccessfullyscaleduptokgamountsneededforfirstclinicalstudies.Key
wastheuseofgalactosyltransferasesandUDP-galactoseforthesynthesisofthetrisaccharide.
Keywords:Carbohydrateantigens·Enzymaticglycosylation·GAS914·Glycopolymer·Xenotransplantation
The availability of human organs for trans-
plantation to treat end-stage organ failure 
is limited to about 25% of patients on wait-
ing lists. This has led to a great interest in 
the possibilities of xenotransplantation 
with the main focus on the pig as donor. 
Although organs from the larger non-hu-
man primates would pose the least immu-
nogenic barrier, ethical considerations as 
well as the high risk of cross-species virus 
transmission preclude such an option.[1] 
On the other hand, the immune reaction to-
wards a pig-to-human xenograft includes 
all branches of the immune system, result-
ing in hyper-acute rejection, acute vascular 
rejection, and – after a period of accom-
modation – cellular rejection as well as 
chronic rejection. The first hurdle – the 
hyper-acute rejection – is initiated within 
minutes upon contact with monoreactive 
naturally existing antibodies directed to 
carbohydrate epitopes, leading to comple-
ment activation and destruction of the or-
gan by hemorrhage and thrombosis within 
hours. These preexisting antibodies origi-
nate from cross-immunization by bacterial 
flora upon colonization of the intestine 
after birth. The predominant antigen is re-
lated to a carbohydrate epitope found on 
proteins and lipids of all mammals except 
primates.[2] This epitope – also called ‘Lin-
ear B’ (1) – is terminated with an a(1,3)-
galactosidic linkage on an unbranched ga-
lactose, i.e. the a(1,2)-linked fucose of hu-
man blood group epitopes (2, 3) is missing 
(Fig. 1). Such variations in glycosylation 
patterns are the result of species-specific 
differences in glycosyl transferase genes. 
The fraction of preformed antibodies di-
rected to these antigens widely differs be-
tween individuals, and can reach 3% of all 
preexisting antibodies.
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The hyper-acute rejection and to a 
large part also the acute vascular rejection 
are caused by anti-Linear-B antibodies 
and the connected complement activa-
tion. One way to overcome this hurdle is 
to breed transgenic animals expressing 
factors regulating complement activation 
such as ‘hDAF’, human decay accelerat-
ing factor,[1a,3] or by depleting the xeno-
reactive antibodies using extracorporeal 
plasmapheresis with affinity columns.[4] 
Another strategy is to ‘inhibit’ these nat-
urally existing antibodies by injection of 
carbohydrate antigen.[5] Such monovalent 
epitopes have, however, to compete with a 
multivalent presentation on cell surfaces, 
e.g. of endothelial cells on blood vessels. 
High concentrations of at least 1 mM have 
to be reached to compete for the xenoanti-
bodies, which are divalent receptors in the 
case of the IgG subclass, and decavalent for 
the pentameric IgM subclass, which plays 
a major role in hyper-acute rejection. The 
well-established principle of multivalent 
potentiation of weak carbohydrate–protein 
interactions[6] should also be operative for 
anti-carbohydrate antibodies. For this pur-
pose attempts with high molecular weight 
oligosaccharides from pig-stomach mu-
cins,[7] with serum albumin conjugates,[8] 
with multivalent arrays on oligo-ethylene 
glycol scaffolds,[9] and with poly-acryl am-
ide conjugates[10] were made.
Our poly-lysine based system, which 
had already been successfully applied 
for potent E-selectin ligands,[11] would be 
well-suited for a multivalent presentation 
of Linear-B. This scaffold has several ad-
vantages over many of the other approach-
es for multivalency. Poly-lysine is com-
mercially available with different degrees 
of polymerization. After derivatization 
a charge-neutral and hydrophilic amide 
linked polymer results, which has a low 
propensity for immunogenicity and is de-
gradable, as opposed to poly-acrylates or 
poly-ethylene glycols. On the other hand, 
albumin conjugates[8] and other proteins 
may be immunogenic, the ethylene glycol 
oligomer carries only eight carbohydrate 
epitopes,[9] and poly-acryl amide with a 
lipophilic backbone is not degradable, and 
the molecular weights have upper limits. 
To prepare poly-lysine conjugates a 
Linear-B oligosaccharide with a 3-ami-
nopropyl aglycon had to be synthesized. 
A purely chemical synthesis using for the 
most part conventional transformations is 
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Scheme1.ChemicalsynthesisofLinear-BtypeIItrisaccharide4withanamino-propylaglycon.
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anol, acetylation, and deprotection finally 
gives the trisaccharide 4. The conjugation 
of Linear-B-propanolamine 4 to poly-
lysine is described in Scheme 2. Reaction 
of 4 with thio-butyrolactone gives thiol 16. 
Commercially available poly-(l)-lysine 
hydrobromide batches 14 with average de-
gree of polymerization n around 40, 250, 
or 1000 are then converted to the DMF-
soluble per-chloroacetamides 15, which in 
turn are coupled with different equivalent 
amounts x of thiolated trisaccharide 16 as 
described previously.[11] The final Linear-B 
conjugates 17 are obtained by capping the 
remaining chloroacetamide groups with 
racemic thioglycerol.[15] The composition 
of these polymeric materials is given by 
the specification of the starting batch of 14 
(vendor), and by 1H-NMR measurements 
at elevated temperatures. Assessment by 
integration of selected signals, assigned to 
either backbone, thioglycerol, or trisaccha-
ride, closely matched the stoichiometry of 
reactants (cf. ref. [11]).
These polymers were then tested in 
vitro for binding avidity with anti-aGal 
antibodies, and in a functional assay for 
inhibiting complement dependent hemo-
lysis of pig erythrocytes by human serum.
[16]
 In binding assays competition for anti-
Linear-B antibodies (pooled human AB-
serum) between antigenic carbohydrate 
coated on well plates and the soluble an-
tigen test compounds is measured with an 
ELISA (enzyme-linked immunosorbent as-
say) format, selective either for the divalent 
IgG or the decavalent IgM subtypes. The 
results shown in Table 1 list inhibitory IC50 
concentrations based on equivalent weight, 
i.e. trisaccharide concentration, rather 
than on molecular weight of the polymer. 
Thus, these equivalent weights are only 
dependent on the fraction x of lysine resi-
dues coupled to saccharide, determined 
by NMR, and are independent of the de-
gree of polymerization n, determined by 
the vendor (SIGMA) by physical methods 
(size exclusion chromatography coupled to 
low angle laser light scattering). Polydis-
persities also specified by the vendor vary 
between 1.1 and 1.2 (cf. also refs [11b,c]). 
It is evident that multivalent arrays 17 in-
hibit anti-Linear-B antibodies better than 
monovalent trisaccharide 4 (entry 1), and 
for most cases also better than the human 
serum albumin (HSA) conjugate tested 
(entry 7). For IgM-binding and inhibition 
of cytotoxicity the potency increases with 
the degree of polymerization n: 36 (entry 
2), 250 (entry 4), and 1050 (entry 6). Also 
25% loading x is better than either 10% or 
60% (entries 3, 4, 5). For the IgG subtype 
a less distinct but similar trend can be seen. 
For the best composition of 17 (entry 6) a 
potency gain of several orders of magnitude 
(2 to 6), compared to monovalent 4, is ob-
served. Further experiments led to the con-
depicted in Scheme 1. The per-acetylated 
tetrachloro-phthalimide-protected glucos-
amine derivative 5[12] is converted to the 
anomeric bromide 6. Helferich-glycosy-
lation of N-benzyloxycarbonyl-protected 
propanolamine 7, deacetylation and trans-
acetalization affords the 4,6-benzal deriva-
tive 8, which is reduced to the 6-O-benzyl 
protected glucosamine 9. By virtue of the 
bulky tetrachloro-phthalimido residue the 
3-hydroxy group need not be protected 
for the regioselective glycosylation of 
the 4-hydroxy group with the Gal-a(1,3)
Gal disaccharide 10. This intermediate is 
obtained by glycosylation of the selec-
tively protected S-ethyl-1-thiogalactose 
derivative 11[13] with trichloro-acetimidate 
12.[14] The crucial glycosylation of 9 with 
glycosyl donor 10 is mediated by activa-
tion with dimethyl-thiomethyl-sulfonium 
trifluoromethyl-sulfonate (DMTST) af-
fording the protected trisaccharide 13 in 
79% yield. Cleavage of the tetrachloro-
phthalimide with ethylene diamine in eth-
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Scheme2.PreparationofLinear-Bpoly-(l)-lysineconjugates17.
Table1.In vitroDataofpoly-(l)-lysineLinear-BtypeIItrisaccharide4 conjugates17
Entry Compound MW
(average)
# Lin-B
per 
Molec.
Equiv.
Weight
IC50
IgG
(μM)
IC50 
IgM
(μM)
IC50 
Hemolysis
(μM)
1 Trisaccharide4 602 1 602 0.7 390.0 397.0
2 Polymer17  
n:36x:0.26
15.5kD ~9 1657 0.02 1.2 1.0
3 Polymer17
n:250x:0.10
83.9kD ~25 3356 0.005 6.0 0.11
4 Polymer17
n:250x:0.25
106.3kD ~62 1700 0.003 0.45 0.02
5 Polymer17
n:250x:0.60
158.4kD ~150 1056 0.2 0.005 0.08
6 Polymer17
n:1050x:0.25
446.3kD ~263 1700 0.007 0.002 0.004
7 HSA-Conjugate
(Dextra)
~70kD ~11 ~6000 0.7
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clusion that the configuration of lysine and 
thioglycerol, as well as the spacer length 
between carbohydrate and backbone play a 
less significant role (data not shown).
First in vivo experiments confirmed 
the superiority of high molecular weight 
poly-lysine conjugates 17. Therefore the 
polymer with 25% carbohydrate loading 
(x: 0.25) and a degree of polymerization n 
between 900 to 1200 entered development 
with the code GAS914. A major technical 
hurdle turned out to be the chemical syn-
thesis of trisaccharide 4 (Scheme 1). In a 
Prep Lab-setting the 24-step sequence with 
six chromatographic separations could be 
scaled up to 20 g of 4. Still, some toxic, 
smelly, or touchy reagents, such as DMTST 
(see above), and the amount of waste es-
timated to 10 tonnes per kg of trisaccha-
ride would make this route a daunting task. 
After some attempts at optimization[17] it 
was decided to resort to enzymatic gly-
cosylations with glycosyl transferases 
and sugar nucleotides as glycosyl donors. 
The advantages of total stereo- and regi-
oselectivity without the need of protect-
ing groups has to be balanced against cost 
and availability of enzymes and activated 
sugars, difficulties of reaction control, re-
producibility, and process scale up. A re-
search procedure starting with Z-protected 
1(3-aminopropyl)-N-acetyl-glucosamine 
18[18] had been elaborated,[19] but needed 
to be optimized for robustness, and toxic 
buffer (Na-cacodylate) should be replaced. 
Also a risk assessment concerning proteins 
of ruminant origin – bovine serum albumin, 
β(1,4)Gal-transferase from cow milk, calf 
intestine alkaline phosphatase – was need-
ed. As shown in Scheme 3, a first galacto-
sylation of 18 with commercially available 
β(1,4)Gal-transferase from cow milk gave 
N-acetyl-lactosamine 19 in 61–89% yield. 
The pH 7.5 cacodylate buffer was success-
fully replaced by acetate buffering at pH 
5.5, a measure which at the same time al-
leviated substrate inhibition. Addition of 
Mg2+ solved the issue of excess of cofac-
tor Mn2+, which otherwise was depleted 
by precipitation of its phosphate. Equally 
successful was the optimization and scale 
up of the second galactosylation with re-
combinant a(1,3)Gal transferase giving the 
Z-protected trisaccharide 20 in 89% yield. 
Crucial here was the quality of the com-
mercial enzyme in respect of minimized 
β-galactosidase activity, which leads back 
to monosaccharide 18. Again the arsenic 
buffer could be replaced by a pH 6.5 ac-
etate buffer. In this case addition of Mg2+ 
was avoided, as it appeared to be connect-
ed with the unwanted glycosidase activity. 
Besides inorganic phosphates uridine 21 
is the only byproduct of these enzymatic 
glycosylations. It is formed by phosphate 
cleavage with CIAP (calf intestine alkaline 
phosphatase) from uridine diphosphate, an 
inhibitor of galactosyl transferases. The 
intermediates 19 and 20 were purified by 
reversed phase chromatography, and a 
crystallization from ethanol/water yield-
ing products of >98% purity. A membrane 
filtration before hydrogenolytic cleavage 
to the target Linear-B propanolamine 4 en-
sured removal of any larger entities such as 
endotoxins, prions, and viral particles. The 
deprotected 3-aminopropyl-trisaccharide 4 
was also amenable to purification by recrys-
tallization from ethanol/water. The remain-
ing steps to the glycopolymer 17 (GAS914) 
followed the research procedure (Scheme 
2) with some adjustments. The thiolated 
oligosaccharide 16 could be isolated by 
crystallization from the concentrated reac-
tion mixture, thereby alleviating the separa-
tion from high boiling thio-butyrolactone. 
This thiol was protected from oxidation 
to disulfide by the addition of antioxidant. 
Isolation of chloro-acetylated poly-(l)-ly-
sine 15 and the final glycopolymer 17 by 
precipitation was a major hurdle. Precipi-
tates were finally obtained in reproducible 
quality by direct precipitation in a stirrable 
pressure filter under high dilution, and re-
dissolving of the product-cake directly on 
the filter. For the final purification by tan-
gential flow ultra filtration compatible filter 
material had to be evaluated. Characteriza-
tion of the product after lyophilization was 
done with NMR, gel permeation chroma-
tography, and in vitro biochemical assays 
for biological properties. The optimized 
procedure thus allowed the preparation of 
kg-quantities of drug substance of suffi-
cient quality to prepare injectable solutions 
for first clinical studies.
In vivo experiments were first done 
with non-human primates – Cynomol-
gus monkeys and baboons – both spe-
cies with preexisting natural antibodies 
against the Linear-B epitope. As shown 
in Fig. 2 (results of one animal) 1 mg/kg 
i.v. injections into Cynomolgus monkeys 
on days 1, 4, and 7 resulted in immediate 
disappearance of circulating antigen spe-
cific antibodies, and also quenched the 
complement dependent hemolytic activ-
ity of treated Cynomolgus monkey serum 
on pig erythrocytes. Antibody levels and 
serum cytotoxicity slowly recovered after 
12 h, but never reached pretreatment lev-
els, even after 28 days. When the same 
animals were treated again at days 105, 
108, and 111, the same depletion/inhibi-
tion was observed, notably without any 
immune response, i.e. without sensitiza-
tion to GAS914.[16] For pharmacokinetic 
studies GAS914 was radiolabelled with 
14C, using 14C-chloroacetic acid for the 
preparation (cf. Scheme 2). In vivo experi-
ments with –/-Gal-T knockout and wild 
type mice, rats, as well as with Rhesus 
monkeys showed a biphasic elimination 
of drug with 95% of radioactivity ex-
creted within minutes in the first phase. 
The second slower phase was species 
dependent with a half life of 30 min for 
mice and 70 h for Rhesus monkeys. In 
the case of animals without anti-Linear-B 
specific antibodies – wild type mice and 
rats – the radioactivity was completely 
cleared by degradation in the liver and 
further degradation and excretion by the 
kidneys. For animals with preformed anti-
Gal specific antibodies – Rhesus monkeys 
and Gal-T knockout mice – clearance was 
essentially identical, but a minute residual 
level of radiolabel was retained in lym-
phoid tissue, spleen and lymph nodes. 
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With the aid of monoclonal antibodies 
raised against the poly-(l)-lysine back-
bone of GAS914 it could be shown with 
immuno-histochemical methods that the 
radioactivity remaining in lymphoid tis-
sue was associated with intact GAS914 
and also co-staining with B-cell regions.
[16]
 It might therefore be speculated that 
such collocation indicates binding of 
GAS914 to B-cells, and suppression of 
anti-Gal antibody production, resulting 
in the observed long term lowering of an-
tibody levels.[16] During these treatments 
no adverse side effects such as immune 
complex mediated glomerulonephritis 
were observed, and complement activa-
tion remained very low. To our knowl-
edge, GAS914 is the most potent inhibitor 
of anti-aGalactosidic carbohydrate anti-
bodies reported. In the case of oligo-eth-
ylene glycol conjugates 50 mg/kg doses 
have to be injected for similar effects,[9] 
and poly-acryl amide conjugates appear 
to be even less efficient, especially for the 
IgG-type antibodies.[10] Furthermore the 
lipophilic backbone of poly-acryl amide 
poses a high risk for immunogenicity, and 
biodegradation is difficult at best.
Polymers analogous to GAS914, also 
with other Gal-(1,3)Gal carbohydrate 
epitopes – disaccharide and pentasaccha-
ride – have been prepared, with an addi-
tional low percentage of lysine side chains 
coupled to a reactive linker (amino group) 
for immobilization on solid supports such 
as Sepharose®. Similar to other immuno 
adsorbents,[4] columns filled with such 
material were less efficient for deplet-
ing serum from anti-Linear-B antibodies 
than GAS914 injections.[20] Subsequent 
pig-to-primate xenotransplantations dem-
onstrated that GAS914 injections consis-
tently removed at least 80% of preexist-
ing natural anti-Linear-B antibodies, thus 
offering a relevant therapeutic option for 
xenotransplantation in general.[21] Even 
better results can be expected, when, in 
addition to GAS914 with Linear-B type II 
carbohydrate epitopes, analogous glyco-
polymers with the related Linear-B type 
VI epitopes would be applied as well. Yet 
another principle to present carbohydrate 
ligands in multivalent arrays is self-assem-
bly of small entities, e.g. lipids or other 
bipolar compounds aggregating to form 
vesicles or liposomes, mimics of cell sur-
faces. We recently discovered that small 
glyco-dendrimers, based on an aromatic 
scaffold, also form aggregates, which bind 
anti-Linear-B antibodies with high avidity, 
comparable with GAS914.[22]
In the past years interest in pig-to-hu-
man xenotransplantation has to some ex-
tent diminished mainly because of the risk 
of transmitting infections by the Porcine 
endogenous retrovirus (PERV).[23] Then 
the successful production of a(1,3)-ga-
lactosyl transferase doubly knockout pigs 
by nuclear transfer cloning[24] was another 
leap forward towards clinical xenotrans-
plantation. Currently the interest is focused 
on transplantation of pig islet cells to treat 
diabetes, or to bridge the waiting time for 
an allograft by 2–6 months with a pig heart 
transplant, thereby replacing mechanical 
devices currently in use. From recent pig-
to-primate transplantations with a(1,3)
Gal-T knockout animals it became evident 
that further genetic modifications would be 
necessary to prolong survival of xenografts 
beyond the six months currently achieved. 
Along these lines anti-coagulant genes 
should prevent thrombotic microangiopa-
thy, causing the majority of organ losses.
[25]
 Yet another complication might be in-
flammation and loss of pig-xenografts by 
infection with Human cytomegalovirus.[26] 
Other options are tolerance induction 
through chimeric bone marrow cells, so 
far restricted to transplantations in early in-
fancy, before establishment of full immune 
competency, or organogenesis from de-
veloping animal organ primordials rather 
than from Human embryonic stem cells.[27] 
Under these circumstances the clinical 
development of GAS914 for eliminat-
ing xeno-antibodies was discontinued. It 
should, however, be noted, that the poly-
lysine backbone of GAS914[11,15] offers an 
excellent base for other antigen-specific 
therapies in antibody mediated diseases, be 
it as injectables or as ligands for immune-
aphaeresis.
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